UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
(Mark One)
☒ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended September 30, 2016
OR
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission File Number: 001-37722
AEGLEA BIOTHERAPEUTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware |
46-4312787 |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer |
901 S. MoPac Expressway Barton Oaks Plaza One Suite 250 Austin, TX 78746 |
|
(Address of principal executive offices including zip code) |
Registrant’s telephone number, including area code: (512) 942-2935
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
|
|
|
|
|||
Non-accelerated filer |
|
☒ (Do not check if a small reporting company) |
|
Small reporting company |
|
☐ |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of November 8, 2016, the registrant had 13,430,833 shares of common stock, $0.0001 par value per share, outstanding.
QUARTERLY REPORT ON FORM 10-Q
FOR THE QUARTER ENDED SEPTEMBER 30, 2016
TABLE OF CONTENTS
|
|
|
Page No. |
|
1 |
||||
|
|
|
|
|
Item 1. |
|
1 |
||
|
|
|
|
|
|
|
Condensed Consolidated Balance Sheets as of September 30, 2016 and December 31, 2015 |
1 |
|
|
|
|
|
|
|
|
2 |
||
|
|
|
|
|
|
|
3 |
||
|
|
|
|
|
|
|
4 |
||
|
|
|
|
|
|
|
5 |
||
|
|
|
|
|
Item 2. |
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
17 |
|
|
|
|
|
|
Item 3. |
|
25 |
||
|
|
|
|
|
Item 4. |
|
25 |
||
|
|
|||
26 |
||||
|
|
|
|
|
Item 1. |
|
26 |
||
|
|
|
|
|
Item 1A. |
|
26 |
||
|
|
|
|
|
Item 2. |
|
56 |
||
|
|
|
|
|
Item 3. |
|
57 |
||
|
|
|
|
|
Item 4. |
|
57 |
||
|
|
|
|
|
Item 5. |
|
57 |
||
|
|
|
|
|
Item 6. |
|
58 |
||
|
|
|
|
|
|
|
59 |
NOTE ABOUT FORWARD-LOOKING STATEMENTS
This quarterly report contains forward-looking statements. All statements other than statements of historical fact are “forward-looking statements” for purposes of this Quarterly Report on Form 10-Q. These forward-looking statements may include, but are not limited to, statements regarding our future results of operations and financial position, business strategy, market size, potential growth opportunities, clinical development activities, efficacy and safety profile of our product candidates, our ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of clinical trials and potential regulatory approval and commercialization of product candidates. The words “believe,” “may,” “will,” “potentially”, “estimate”, “continue”, “anticipate,” “predict,” “target,” “intend,” “could,” “would,” “should,” “project,” “plan,” “expect,” and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in “Risk Factors” and elsewhere in this quarterly report. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this quarterly report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.
You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to actual results or to changes in our expectations, except as required by law.
As used in this Quarterly Report on Form 10-Q, the terms “Aeglea,” “the Company,” “we,” “us,” and “our” refer to Aeglea BioTherapeutics, Inc. and, where appropriate, its consolidated subsidiaries, unless the context indicates otherwise.
PART I. – FINANCIAL INFORMATION
Aeglea BioTherapeutics, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(In thousands, except share and per share amounts)
|
|
September 30, |
|
|
December 31, |
|
||
|
|
2016 |
|
|
2015 |
|
||
ASSETS |
|
|
|
|
|
|
|
|
CURRENT ASSETS |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
49,544 |
|
|
$ |
29,294 |
|
Marketable securities |
|
|
18,491 |
|
|
|
3,768 |
|
Restricted cash |
|
|
— |
|
|
|
80 |
|
Accounts receivable - grant |
|
|
1,571 |
|
|
|
1,697 |
|
Deferred offering costs |
|
|
— |
|
|
|
2,535 |
|
Prepaid expenses and other current assets |
|
|
2,073 |
|
|
|
912 |
|
Total current assets |
|
|
71,679 |
|
|
|
38,286 |
|
Property and equipment, net |
|
|
342 |
|
|
|
348 |
|
Other non-current assets |
|
|
40 |
|
|
|
20 |
|
TOTAL ASSETS |
|
$ |
72,061 |
|
|
$ |
38,654 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS’ EQUITY (DEFICIT) |
|
|||||||
CURRENT LIABILITIES |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
523 |
|
|
$ |
176 |
|
Deferred revenue |
|
|
181 |
|
|
|
— |
|
Accrued and other current liabilities |
|
|
3,133 |
|
|
|
2,347 |
|
Total current liabilities |
|
|
3,837 |
|
|
|
2,523 |
|
Other non-current liabilities |
|
|
26 |
|
|
|
27 |
|
TOTAL LIABILITIES |
|
|
3,863 |
|
|
|
2,550 |
|
Commitments and Contingencies (Note 11 and 13) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Series A convertible preferred stock, $0.0001 par value; no shares and 2,172,524 shares authorized as of September 30, 2016 and December 31, 2015, respectively; no shares and 2,172,520 shares issued and outstanding as of September 30, 2016 and December 31, 2015, respectively |
|
|
— |
|
|
|
13,573 |
|
Series B convertible preferred stock, $0.0001 par value; no shares and 5,008,210 shares authorized as of September 30, 2016 and December 31, 2015, respectively; no shares and 4,999,976 shares issued and outstanding as of September 30, 2016 and December 31, 2015, respectively |
|
|
— |
|
|
|
44,738 |
|
|
|
|
|
|
|
|
|
|
STOCKHOLDERS’ EQUITY (DEFICIT) |
|
|
|
|
|
|
|
|
Preferred stock, $0.0001 par value; 10,000,000 shares and no shares authorized as of September 30, 2016 and December 31, 2015, respectively; no shares issued and outstanding as of September 30, 2016 and December 31, 2015, respectively |
|
|
— |
|
|
|
— |
|
Common stock, $0.0001 par value; 500,000,000 shares and 25,000,000 shares authorized as of September 30, 2016 and December 31, 2015, respectively; 13,430,833 shares and 757,336 shares issued and outstanding as of September 30, 2016 and December 31, 2015, respectively |
|
|
1 |
|
|
|
— |
|
Additional paid-in capital |
|
|
107,988 |
|
|
|
1,373 |
|
Accumulated other comprehensive income (loss) |
|
|
3 |
|
|
|
(1 |
) |
Accumulated deficit |
|
|
(39,794 |
) |
|
|
(23,579 |
) |
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT) |
|
|
68,198 |
|
|
|
(22,207 |
) |
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS’ EQUITY (DEFICIT) |
|
$ |
72,061 |
|
|
$ |
38,654 |
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
1
Condensed Consolidated Statements of Operations
(Unaudited)
(In thousands, except share and per share amounts)
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||
|
|
2016 |
|
|
2015 |
|
|
2016 |
|
|
2015 |
|
||||
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Grant |
|
$ |
1,149 |
|
|
$ |
1,073 |
|
|
$ |
3,381 |
|
|
$ |
4,500 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
$ |
5,385 |
|
|
$ |
3,129 |
|
|
$ |
13,402 |
|
|
$ |
7,487 |
|
General and administrative |
|
|
2,065 |
|
|
|
1,361 |
|
|
|
6,342 |
|
|
|
4,331 |
|
Total operating expenses |
|
|
7,450 |
|
|
|
4,490 |
|
|
|
19,744 |
|
|
|
11,818 |
|
Loss from operations |
|
|
(6,301 |
) |
|
|
(3,417 |
) |
|
|
(16,363 |
) |
|
|
(7,318 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income |
|
|
72 |
|
|
|
5 |
|
|
|
172 |
|
|
|
11 |
|
Other expense, net |
|
|
(9 |
) |
|
|
(1 |
) |
|
|
(24 |
) |
|
|
(1 |
) |
Total other income |
|
|
63 |
|
|
|
4 |
|
|
|
148 |
|
|
|
10 |
|
Net loss |
|
$ |
(6,238 |
) |
|
$ |
(3,413 |
) |
|
$ |
(16,215 |
) |
|
$ |
(7,308 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deemed dividend to convertible preferred stockholders |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(228 |
) |
Net loss attributable to common stockholders |
|
$ |
(6,238 |
) |
|
$ |
(3,413 |
) |
|
$ |
(16,215 |
) |
|
$ |
(7,536 |
) |
Net loss per share attributable to common stockholders, basic and diluted |
|
$ |
(0.47 |
) |
|
$ |
(5.57 |
) |
|
$ |
(1.89 |
) |
|
$ |
(12.76 |
) |
Weighted-average common shares outstanding, basic and diluted |
|
|
13,326,093 |
|
|
|
612,917 |
|
|
|
8,598,268 |
|
|
|
590,775 |
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
2
Condensed Consolidated Statements of Comprehensive Loss
(Unaudited)
(In thousands)
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||
|
|
2016 |
|
|
2015 |
|
|
2016 |
|
|
2015 |
|
||||
Net loss |
|
$ |
(6,238 |
) |
|
$ |
(3,413 |
) |
|
$ |
(16,215 |
) |
|
$ |
(7,308 |
) |
Other comprehensive income: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized gain on marketable securities |
|
|
2 |
|
|
|
2 |
|
|
|
4 |
|
|
|
2 |
|
Total comprehensive loss |
|
$ |
(6,236 |
) |
|
$ |
(3,411 |
) |
|
$ |
(16,211 |
) |
|
$ |
(7,306 |
) |
The accompanying notes are an integral part of these condensed consolidated financial statements.
3
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(In thousands)
|
|
Nine Months Ended September 30, |
|
|||||
|
|
2016 |
|
|
2015 |
|
||
CASH FLOWS FROM OPERATING ACTIVITIES |
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(16,215 |
) |
|
$ |
(7,308 |
) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
96 |
|
|
|
60 |
|
Purchase premium on marketable securities |
|
|
(146 |
) |
|
|
(5 |
) |
Amortization of premium on marketable securities |
|
|
51 |
|
|
|
1 |
|
Loss on disposal of property and equipment |
|
|
1 |
|
|
|
2 |
|
Deferred rent |
|
|
— |
|
|
|
3 |
|
Amortization of lease allowance liability |
|
|
(17 |
) |
|
|
(17 |
) |
Stock-based compensation |
|
|
963 |
|
|
|
348 |
|
Research and development services settled with convertible preferred stock |
|
|
80 |
|
|
|
695 |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
Accounts receivable-grant |
|
|
126 |
|
|
|
(4,235 |
) |
Prepaid expenses and other assets |
|
|
(1,261 |
) |
|
|
(528 |
) |
Accounts payable |
|
|
347 |
|
|
|
217 |
|
Deferred revenue |
|
|
181 |
|
|
|
— |
|
Accrued and other liabilities |
|
|
1,309 |
|
|
|
618 |
|
Net cash used in operating activities |
|
|
(14,485 |
) |
|
|
(10,149 |
) |
CASH FLOWS FROM INVESTING ACTIVITIES |
|
|
|
|
|
|
|
|
Purchases of property and equipment |
|
|
(91 |
) |
|
|
(168 |
) |
Purchases of marketable securities |
|
|
(20,390 |
) |
|
|
(3,296 |
) |
Proceeds from maturities of marketable securities |
|
|
5,766 |
|
|
|
— |
|
Decrease (increase) in restricted cash |
|
|
80 |
|
|
|
(40 |
) |
Net cash used in investing activities |
|
|
(14,635 |
) |
|
|
(3,504 |
) |
CASH FLOWS FROM FINANCING ACTIVITIES |
|
|
|
|
|
|
|
|
Proceeds from issuance of convertible preferred stock, net of offering costs |
|
|
— |
|
|
|
43,679 |
|
Proceeds from initial public offering, net of (payments of) offering costs |
|
|
49,294 |
|
|
|
(1,802 |
) |
Proceeds from employee stock plan purchases |
|
|
76 |
|
|
|
— |
|
Net cash provided by financing activities |
|
|
49,370 |
|
|
|
41,877 |
|
NET INCREASE IN CASH |
|
|
20,250 |
|
|
|
28,224 |
|
|
|
|
|
|
|
|
|
|
CASH |
|
|
|
|
|
|
|
|
Beginning of period |
|
|
29,294 |
|
|
|
2,616 |
|
End of period |
|
$ |
49,544 |
|
|
$ |
30,840 |
|
Supplemental Disclosure of Non-Cash Investing and Financing Information: |
|
|
|
|
|
|
|
|
Deemed dividend to Series A convertible preferred stockholders upon conversion from an LLC to corporation |
|
$ |
— |
|
|
$ |
228 |
|
Convertible preferred stock issued for research and development services to be performed |
|
$ |
— |
|
|
$ |
349 |
|
Conversion of Series A convertible preferred stock to common stock upon initial public offering |
|
$ |
13,573 |
|
|
$ |
— |
|
Conversion of Series B convertible preferred stock to common stock upon initial public offering |
|
$ |
44,738 |
|
|
$ |
— |
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
4
Notes to Condensed Consolidated Financial Statements
1. The Company and Basis of Presentation
Aeglea BioTherapeutics, Inc. (“Aeglea” or the “Company”) is an early-stage biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism that it believes will transform the lives of patients with cancer and inborn errors of metabolism, a subset of rare genetic metabolic diseases. The Company was formed as a Limited Liability Company (LLC) in Delaware on December 16, 2013 under the name Aeglea BioTherapeutics Holdings, LLC (“Aeglea LLC”) and was converted from a Delaware LLC to a Delaware corporation (the “LLC Conversion”) on March 10, 2015. The Company operates in one segment and has its principal offices in Austin, Texas.
Initial Public Offering
On April 6, 2016, the Company’s Registration Statement on Form S-1 (File No. 333-205001) relating to the initial public offering (“IPO”) of its common stock was declared effective by the Securities and Exchange Commission (“SEC”). The IPO closed on April 12, 2016, and 5,481,940 shares of common stock were sold at a public offering price of $10.00 per share, including 481,940 shares of common stock issued upon the partial exercise by the underwriters of their option to purchase additional shares. The Company received $47.3 million in aggregate cash proceeds, net of underwriting discounts and commissions of $3.8 million and offering costs of $3.7 million incurred by the Company.
Immediately prior to the closing of the IPO, all shares of outstanding convertible preferred stock were automatically converted, at a ratio of one share of common stock for each share of convertible preferred stock, into 7,172,496 shares of common stock with the related carrying value of $58.3 million reclassified to common stock and additional paid-in capital.
In connection with the IPO, the Company amended its Restated Certificate of Incorporation (the “Public Certificate”) to change the authorized capital stock to 510,000,000 shares of which 500,000,000 shares are designated as common stock and 10,000,000 shares are designated as preferred stock, all with a par value of $0.0001 per share. There are no shares of preferred stock outstanding as of September 30, 2016.
Reverse Stock Split
The Company’s Board of Directors and stockholders approved a 1-for-10.5 reverse stock split of the Company’s common stock and preferred stock. The reverse stock split became effective on March 28, 2016 upon filing an amended Restated Certificate of Incorporation (the “Split Certificate”). The Split Certificate remained in effect until closing of the IPO, at which time the company amended the Restated Certificate of Incorporation and filed the Public Certificate.
All share and per share amounts in the condensed consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital.
Liquidity
As of September 30, 2016, the Company had working capital of $67.8 million, an accumulated deficit of $39.8 million, and cash, cash equivalents, and marketable securities of $68.0 million. The Company has not generated any product revenues and has not achieved profitable operations. There is no assurance that profitable operations will ever be achieved, and, if achieved, could be sustained on a continuing basis. In addition, development activities, clinical and nonclinical testing, and commercialization of the Company’s products will require significant additional financing.
The Company believes that its existing cash, cash equivalents, and marketable securities will be sufficient to enable the Company to continue as a going concern for at least 12 months beyond September 30, 2016. However, the Company will need to secure additional funding in the future, in order to carry out all of its planned research and development activities. If the Company is unable to obtain additional financing or generate license or product revenue, the lack of liquidity could have a material adverse effect on the Company’s future prospects.
Unaudited Interim Financial Information
The interim condensed consolidated financial statements included in this document are unaudited. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for a fair statement of the
5
Company’s financial position as of September 30, 2016, and its results of operations for the three months and nine months ended September 30, 2016 and 2015, and cash flows for the nine months ended September 30, 2016 and 2015. The results of operations for the nine months ended September 30, 2016 are not necessarily indicative of the results to be expected for the year ending December 31, 2016 or for any other future annual or interim period. The December 31, 2015 balance sheet was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States (“U.S. GAAP”). These financial statements should be read in conjunction with the audited financial statements included in the Company’s Prospectus dated April 6, 2016 filed with the SEC pursuant to Rule 424(b)(4) (the “Prospectus”).
2. Summary of Significant Accounting Policies
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Such management estimates include those related to accruals of research and development related costs, fair values of preferred and common stock, stock-based compensation, and certain company income tax related items. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ significantly from those estimates.
Risks and Uncertainties
The product candidates being developed by the Company require approvals from the U.S. Food and Drug Administration (“FDA”) or foreign regulatory agencies prior to commercial sales. There can be no assurance that the Company’s product candidates will receive the necessary approvals. If the Company is denied regulatory approval of its product candidates, or if such approvals are delayed, it may have a material adverse impact on the Company’s business, results of operations and its financial position.
The Company is subject to a number of risks similar to other life science companies, including, but not limited to, risks related to the successful discovery and development of product candidates, raising additional capital, development of competing drugs and therapies, protection of proprietary technology and market acceptance of the Company’s products. As a result of these and other factors and the related uncertainties, there can be no assurance of the Company’s future success.
Cash and Cash Equivalents
The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist of money market funds and debt securities and are stated at fair value.
Marketable Securities
All investments have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments in debt securities at the time of purchase. Unrealized gains and losses are excluded from earnings and are reported as a component of accumulated comprehensive loss. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in other income (expense). The cost of securities sold is based on the specific-identification method. There were no realized gains or losses on marketable securities for the nine months ended September 30, 2016 and 2015. Interest on marketable securities is included in interest income.
Restricted Cash
Restricted cash consisted of a money market account held by a financial institution as collateral for the Company’s obligations under a corporate credit card agreement. In September 2016, the collateral requirement was terminated and the restricted cash balance was transferred to cash and cash equivalents.
6
Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, and marketable securities. The Company’s investment policy limits investments to high credit quality securities issued by the U.S. government, U.S. government-sponsored agencies and highly rated banks, subject to certain concentration limits and restrictions on maturities. The Company’s cash, cash equivalents, and marketable securities are held by financial institutions in the United States that management believes are of high credit quality. Amounts on deposit may at times exceed federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its accounts are monitored by management to mitigate risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents and bond issuers.
Deferred Offering Costs
Deferred offering costs, which primarily consist of direct incremental legal, printing, and accounting fees relating to the Company’s IPO of its common stock, are capitalized. At the closing of the IPO, the deferred offering costs were offset against the proceeds from the IPO and recorded to additional paid-in capital.
Property and Equipment
Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets. Repairs and maintenance that do not extend the life or improve an asset are expensed as incurred. Upon retirement or sale, the cost of disposed assets and their related accumulated depreciation and amortization are removed from the balance sheet. Any gain or loss is credited or charged to operations.
The useful lives of the property and equipment are as follows:
Laboratory equipment |
|
5 years |
Furniture and office equipment |
|
5 years |
Computer equipment |
|
3 years |
Software |
|
3 years |
Leasehold improvements |
|
Shorter of remaining lease term or estimated useful life |
Impairment of Long-Lived Assets
Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable, and the carrying amount exceeds the projected discounted future cash flows arising from these assets. There were no impairments of long-lived assets for the nine months ended September 30, 2016 and 2015.
Accrued Research and Development Costs
The Company records the costs associated with research nonclinical studies, clinical trials, and manufacturing development as incurred. These costs are a significant component of the Company’s research and development expenses, with a substantial portion of the Company’s on-going research and development activities conducted by third-party service providers, including contract research and manufacturing organizations.
The Company accrues for expenses resulting from obligations under agreements with contract research organizations (“CROs”), contract manufacturing organizations (“CMOs”), and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. The Company makes significant judgments and estimates in determining the accrual balance in each reporting period. In the event advance payments are made to a CRO, CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals. Inputs, such as the services performed, the number of patients enrolled, or the study duration, may vary from the Company’s estimates, resulting in
7
adjustments to research and development expense in future periods. Changes in these estimates that result in material changes to the Company’s accruals could materially affect the Company’s results of operations. The Company has not experienced any material deviations between accrued and actual research and development expenses.
Leases
The Company entered into a lease agreement for its office facilities. The lease is classified as an operating lease. The Company records rent expense on a straight-line basis over the term of the lease and, accordingly records the difference between cash rent payments and the recognition of rent expense as a deferred rent liability. Incentives granted under the Company’s facilities leases, including allowances to fund leasehold improvements, are deferred and are recognized as adjustments to rental expense on a straight-line basis over the term of the lease.
Fair Value of Financial Instruments
The Company uses fair value measurements to record fair value adjustments to certain financial and non-financial assets and liabilities and to determine fair value disclosures. The accounting standards define fair value, establish a framework for measuring fair value, and require disclosures about fair value measurements. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the principal or most advantageous market in which the Company would transact are considered along with assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance.
The accounting standard for fair value establishes a fair value hierarchy based on three levels of inputs, the first two of which are considered observable and the last unobservable, that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
The three levels of inputs that may be used to measure fair value are as follows:
|
Level 1: |
Observable inputs, such as quoted prices in active markets for identical assets or liabilities. |
|
Level 2: |
Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. |
|
Level 3: |
Valuations based on unobservable inputs to the valuation methodology and including data about assumptions market participants would use in pricing the asset or liability based on the best information available under the circumstances. |
Financial instruments carried at fair value include cash, cash equivalents, and marketable securities. The carrying amount of accounts receivable, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.
Convertible Preferred Stock
The Company recorded the issuance of all convertible preferred stock net of offering costs on the dates of issuance, which represented the carrying value. The conversion feature of the convertible preferred stock was subject to certain anti-dilution provisions, which if triggered, would have required the Company to seek shareholder approval to increase the number of shares of common stock authorized. In the event that the Company could not deliver the conversion shares because it did not have an adequate number of common stock authorized, the convertible preferred stock would have been redeemable. Accordingly, the Company classified the convertible preferred stock in temporary equity. The Company did not adjust the carrying value of the convertible preferred stock to their redemption values, since it was uncertain whether or when a redemption event would occur. The convertible preferred stock outstanding was automatically converted into shares of common stock immediately prior to the completion of the IPO in April 2016 (see Note 1).
Revenue Recognition
The Company’s sole source of revenue is grant revenue related to a $19.8 million research grant received from the Cancer Prevention and Research Institute of Texas (“CPRIT”), covering a three year period from June 1, 2014 through May 31, 2017. Grant revenue is recognized when qualifying costs are incurred and there is reasonable assurance that the
8
conditions of the award have been met for collection. Proceeds received prior to the costs being incurred or the conditions of the award being met are recognized as deferred revenue until the services are performed and the conditions of the award are met (see Note 6).
Research and Development Costs
Research and development costs are expensed as incurred. Research and development costs include, but are not limited to, salaries, benefits, travel, share-based compensation, consulting costs, contract research service costs, laboratory supplies, contract manufacturing costs, and costs paid to other third parties that conduct research and development activities on the Company’s behalf. Amounts incurred in connection with license agreements are also included in research and development expense.
Certain research and development costs incurred were settled contractually by the Company issuing a variable number of the Company’s shares determined by dividing the fixed monetary amount of costs incurred by the issuance-date fair value of the issuable shares. The Company recorded research and development expense for these costs and accrued for the fixed monetary amount as an accrued liability as the services were rendered until the amount was settled. In June 2015, the remaining Company obligation to settle these costs with Company shares was converted to a cash-based payment through a contract amendment with the service provider.
Advance payments for goods or services to be rendered in the future for use in research and development activities are recorded as a prepaid asset and expensed as the related goods are delivered or the services are performed.
Stock-Based Compensation
The Company recognizes the cost of stock-based awards granted to employees based on the estimated grant-date fair values of the awards. The value of the portion of the award that is ultimately expected to vest is recognized as expense ratably over the requisite service period. The Company recognizes the compensation costs for awards that vest over several years on a straight-line basis over the vesting period. The Company recognizes the cost of stock-based awards granted to nonemployees at their then-current fair values as services are performed, and are remeasured through the counterparty performance date.
Income Taxes
Effective January 1, 2015, the Company, for tax purposes, converted from a partnership to a corporation and continues to serve as a holding company for seven wholly-owned subsidiary corporations. Beginning with the year ended December 31, 2015, the Company filed a consolidated corporate federal income tax return. The Company and its subsidiaries use the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements and the tax bases of assets and liabilities. A valuation allowance is established against the deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. The deferred tax assets and liabilities are classified as noncurrent along with the related valuation allowance. Due to a lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance.
The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on the technical merits, as the largest amount of benefits that is more likely than not be realized upon the ultimate settlement. The Company’s policy is to recognize interest and penalties related to the unrecognized tax benefits as a component of income tax expense. To date, there have been no interest or penalties recognized in relation to the unrecognized tax benefits.
Comprehensive Loss
Comprehensive loss is the change in stockholders’ equity (deficit) from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to stockholders. The Company’s other comprehensive income (loss) is currently comprised of changes in unrealized gains and losses on available-for-sale securities.
9
Certain reclassifications have been made to prior period amounts to conform to current period presentation. These reclassifications did not have an impact on the Company’s results of operations or financial position as of September 30, 2016 and December 31, 2015.
Recent Accounting Pronouncements
In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern, which will require management to assess, at each annual and interim reporting period, the entity’s ability to continue as a going concern. The amendments in ASU 2014-15 do not have any application to an entity’s financial statements, but only to disclosure in the related notes. ASU 2014-15 is effective for annual and interim periods ending after December 15, 2016 and early application is permitted. The Company intends to apply ASU 2014-15 in the first quarter of 2017 and for the annual period ending December 31, 2016.
In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which establishes a comprehensive new lease accounting model. The new standard: (a) clarifies the definition of a lease; (b) requires a dual approach to lease classification similar to current lease classifications; and, (c) causes lessees to recognize leases on the balance sheet as a lease liability with a corresponding right-of-use asset for leases with a lease-term of more than twelve months. The new standard is effective for fiscal years and interim periods beginning after December 15, 2018 and requires modified retrospective application. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU 2016-02 will have on its consolidated financial statements.
In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification of awards as either equity or liabilities, classification on the statement of cash flows and forfeitures. The standard is effective for fiscal years and interim periods beginning after December 15, 2016. Early adoption is permitted. The Company is currently evaluating the impact that the standard will have on its consolidated financial statements.
3. Cash Equivalents and Marketable Securities
The following tables summarize the estimated fair value of our cash equivalents and marketable securities and the gross unrealized gains and losses (in thousands):
|
|
September 30, 2016 |
|
|||||||||||||
|
|
Amortized Cost |
|
|
Gross Unrealized Gains |
|
|
Gross Unrealized Losses |
|
|
Estimated Fair Value |
|
||||
Cash equivalents: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Money market funds |
|
$ |
5,290 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
5,290 |
|
Reverse repurchase agreements |
|
|
39,250 |
|
|
|
— |
|
|
|
— |
|
|
|
39,250 |
|
US government and agency securities |
|
|
1,000 |
|
|
|
— |
|
|
|
— |
|
|
|
1,000 |
|
Total cash equivalents |
|
|
45,540 |
|
|
|
— |
|
|
|
— |
|
|
|
45,540 |
|
Marketable securities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US government and agency securities |
|
|
18,488 |
|
|
|
4 |
|
|
|
(1 |
) |
|
|
18,491 |
|
Total marketable securities |
|
$ |
18,488 |
|
|
$ |
4 |
|
|
$ |
(1 |
) |
|
$ |
18,491 |
|
|
|
December 31, 2015 |
|
|||||||||||||
|
|
Amortized Cost |
|
|
Gross Unrealized Gains |
|
|
Gross Unrealized Losses |
|
|
Estimated Fair Value |
|
||||
Cash equivalents: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Money market funds |
|
$ |
3,988 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
3,988 |
|
Reverse repurchase agreements |
|
|
16,250 |
|
|
|
— |
|
|
|
— |
|
|
|
16,250 |
|
Total cash equivalents |
|
|
20,238 |
|
|
|
— |
|
|
|
— |
|
|
|
20,238 |
|
Marketable securities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US government and agency securities |
|
|
3,769 |
|
|
|
— |
|
|
|
(1 |
) |
|
|
3,768 |
|
Total marketable securities |
|
$ |
3,769 |
|
|
$ |
— |
|
|
$ |
(1 |
) |
|
$ |
3,768 |
|
10
All of the cash equivalents and marketable securities held as of September 30, 2016 and December 31, 2015 had maturities of less than one year.
As of September 30, 2016 and December 31, 2015, the Company held two and five debt securities, respectively, that were in an unrealized loss position for less than one year. The aggregate fair value of debt securities in an unrealized loss position as of September 30, 2016 and December 31, 2015 were $3.8 million and $2.5 million, respectively, with no individual securities in a significant unrealized loss position. The Company evaluated its securities for other-than-temporary impairment and considered the decline in market value for the securities to be primarily attributable to current economic and market conditions and would not be required to sell the securities before recovery of the amortized cost basis. Based on this analysis, these marketable securities were not considered to be other-than-temporarily impaired as of September 30, 2016 and December 31, 2015.
4. Accrued and Other Current Liabilities
Accrued and other current liabilities consist of the following (in thousands):
|
|
September 30, |
|
|
December 31, |
|
||
|
|
2016 |
|
|
2015 |
|
||
Accrued compensation |
|
$ |
895 |
|
|
$ |
571 |
|
Accrued contracted research and development costs |
|
|
1,699 |
|
|
|
863 |
|
Accrued professional and consulting fees |
|
|
374 |
|
|
|
863 |
|
Accrued other and other current liabilities |
|
|
165 |
|
|
|
50 |
|
Total accrued and other current liabilities |
|
$ |
3,133 |
|
|
$ |
2,347 |
|
5. Convertible Preferred Stock
On April 12, 2016, immediately prior to the closing of the IPO, all of the Company’s outstanding convertible preferred stock was automatically converted into an aggregate total of 7,172,496 shares of common stock (see Note 1).
On March 10, 2015, the Company converted from a Delaware limited liability company into a Delaware corporation and changed the Company’s name from Aeglea BioTherapeutics Holdings, LLC to Aeglea BioTherapeutics, Inc. In connection with the LLC Conversion, all of the Company’s outstanding common shares and convertible preferred shares were converted into shares of common stock and convertible preferred stock. Upon the LLC Conversion, each then-outstanding Series A convertible preferred share was converted into one share of Series A convertible preferred stock, par value $0.0001 per share. The Company determined that the LLC Conversion resulted in a deemed dividend from stockholders of common stock to stockholders of Series A convertible preferred stock of $0.11 per share of Series A convertible preferred stock. The Company recorded $228,000 as an increase in the carrying amount of the Series A convertible preferred stock and as a reduction of additional paid-in capital. Such dividend was determined by comparing the fair value of the Series A convertible preferred shares immediately prior to the conversion to the fair value of the Series A convertible preferred stock issued in the conversion.
Also on March 10, 2015, the Company issued 4,929,948 shares of Series B convertible preferred stock, par value $0.0001 per share, at an issuance price equal to $8.93 per share and received gross proceeds of $44.0 million. In connection with the financing, the Company incurred total offering costs of $321,000.
6. Grant Revenues
In June 2015, the Company entered into a Cancer Research Grant Contract (“Grant Contract”) with CPRIT, under which CPRIT awarded a grant not to exceed $19.8 million for use in developing cancer treatments by exploiting the metabolism of cancer cells. The Grant Contract covers a three year period from June 1, 2014 through May 31, 2017.
Upon commercialization of the product, the terms of the Grant Contract require the Company to pay tiered royalties in the low to mid-single digit percentages. Such royalties reduce to less than one percent after a mid-single-digit multiple of the grant funds have been paid to CPRIT in royalties.
The agreement includes reimbursement for qualified expenditures incurred and recognized in 2014. Upon execution of the Grant Contract, grant revenue was recognized for the accumulated qualified expenditures paid and recognized in
11
the period from June 1, 2014 through June 30, 2015. The Company recognized grant revenue of $1.2 million and $1.1 million in the three months ended September 30, 2016 and 2015, respectively, and $3.4 million and $4.5 million in the nine months ended September 30, 2016 and 2015, respectively, for qualified expenditures under the grant. As of September 30, 2016 and December 31, 2015, the Company had an outstanding grant receivable of $1.6 million and $1.7 million, respectively, for the grant expenditures that were paid but had not been reimbursed and deferred revenue of $0.2 million and $0, respectively, for proceeds received but the costs had not been incurred or the conditions of the award had not been met.
7. Stock-Based Compensation
2016 Equity Incentive Plan
On April 5, 2016, the day preceding the effectiveness of the Registration Statement, the 2016 Equity Incentive Plan (the “2016 Plan”) became effective and serves as the successor to the 2015 Equity Incentive Plan (the “2015 Plan”). Under the 2016 Plan, the Company may grant stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance awards, and stock bonuses. A total of 1,100,000 shares of common stock were reserved for issuance under the 2016 Plan. The shares reserved exclude shares of common stock reserved for issuance under the 2015 Plan. Shares totaling 509,869 that were remaining under the 2015 Plan were added to the shares initially reserved under the 2016 Plan upon its effectiveness. In addition, the number of shares of stock available for issuance under the 2016 Plan may be increased each January 1, beginning on January 1, 2017 and continuing through 2023, by 4% of the outstanding number of shares of the Company’s common stock on the immediately preceding December 31 or such lesser number as determined by the Company’s board of directors. No further stock option or other awards may be granted under the 2015 Plan.
2016 Employee Stock Purchase Plan
On April 6, 2016, upon the effectiveness of the Registration Statement, the 2016 Employee Stock Purchase Plan (the “2016 ESPP”) became effective. A total of 165,000 shares of common stock were reserved for issuance under the 2016 ESPP. Eligible employees may purchase shares of common stock under the 2016 ESPP at 85% of the lower of the fair market value of the Company’s common stock as of the first or the last day of each offering period. Employees are limited to contributing 15% of the employee’s eligible compensation, and may not purchase more than $25,000 of stock during any calendar year or more than 2,000 shares during any one purchase period or a lesser amount determined by the board of directors. The 2016 ESPP will terminate ten years from the first purchase date under the plan, unless terminated earlier by the board of directors. During the three months and nine months ended September 30, 2016, the Company issued and sold 19,061 shares under the 2016 ESPP. The remaining 145,939 shares are available for issuance as of September 30, 2016.
Stock Options
In May 2016, the Company’s board of directors approved the modification of 542,392 outstanding stock options for 21 employees to align the vesting schedule of existing awards with the Company’s planned vesting schedule for future awards. The result was an acceleration of vesting for the modified awards. Stock options with a five year vesting schedule and 25% vesting after year two and 6.25% quarterly thereafter were modified to a four year vesting schedule with 25% vesting after year one and 2.08% monthly thereafter. Stock options with a four year vesting schedule and 25% vesting after year one and 6.25% quarterly thereafter were modified to a similar four year vesting schedule with 25% vesting after year one and 2.08% monthly thereafter. The modified awards have service conditions only.
In accordance with ASC 718, the Company determined the fair value of the awards immediately before the modification and compared that amount to the then fair value of the modified awards. Given there was no incremental fair value in connection with the modification of the awards, the Company will continue to recognize the compensation expense originally estimated for the stock options at the date of grant over the modified service period. The Company recognized $89,000 in cumulative expense as of the modification date related to changes in the service period for the modified awards.
During the three months ended September 30, 2016, the Company issued an aggregate of 11,562 options to purchase common stock under its equity incentive plans for an aggregate fair value of $42,000. There were no options issued during the three months ended September 30, 2015.
12
During the nine months ended September 30, 2016 and 2015, the Company issued an aggregate of 731,779 and 644,505 options, respectively, to purchase common stock under its equity incentive plans for an aggregate fair value of $3.7 million and $2.1 million, respectively.
Total stock-based compensation expense related to the Company’s equity incentive plans and 2016 ESPP was as follows (in thousands):
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||
|
|
2016 |
|
|
2015 |
|
|
2016 |
|
|
2015 |
|
||||
Research and development |
|
$ |
190 |
|
|
$ |
43 |
|
|
$ |
400 |
|
|
$ |
129 |
|
General and administrative |
|
|
244 |
|
|
|
121 |
|
|
|
563 |
|
|
|
219 |
|
Total stock-based compensation expense |
|
$ |
434 |
|
|
$ |
164 |
|
|
$ |
963 |
|
|
$ |
348 |
|
The following table summarizes the weighted-average Black-Scholes option pricing model assumptions used to estimate the fair value of stock options granted under the 2016 Plan and 2015 Plan and the shares purchasable under the 2016 ESPP during the periods presented:
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||
|
|
2016 |
|
|
2015 |
|
|
2016 |
|
|
2015 |
|
||||
2016 Plan and 2015 Plan |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expected term |
|
|
6.07 |
|
|
|
— |
|
|
|
5.99 |
|
|
|
6.29 |
|
Expected volatility |
|
|
81 |
% |
|
|
— |
|
|
|
87 |
% |
|
|
87 |
% |
Risk-free interest |
|
|
1.16 |
% |
|
|
— |
|
|
|
1.28 |
% |
|
|
1.37 |
% |
Dividend yield |
|
|
0 |
% |
|
|
— |
|
|
|
0 |
% |
|
|
0 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2016 ESPP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expected term |
|
|
0.50 |
|
|
|
— |
|
|
|
0.45 |
|
|
|
— |
|
Expected volatility |
|
|
81 |
% |
|
|
— |
|
|
|
82 |
% |
|
|
— |
|
Risk-free interest |
|
|
0.57 |
% |
|
|
— |
|
|
|
0.49 |
% |
|
|
— |
|
Dividend yield |
|
|
0 |
% |
|
|
— |
|
|
|
0 |
% |
|
|
— |
|
8. Defined Contribution Plan
In September 2016, the Company began to sponsor a 401(k) retirement plan in which substantially all of its full-time employees are eligible to participate. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. The Company did not provide any contributions to the plan during the nine months ended September 30, 2016.
9. Fair Value Measurements
The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. The following tables sets forth the fair value of the Company’s financial assets and liabilities at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands):
|
|
September 30, 2016 |
|
|||||||||||||
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
||||
Financial Assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Money market funds |
|
$ |
5,290 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
5,290 |
|
Reverse repurchase agreements |
|
|
— |
|
|
|
39,250 |
|
|
|
— |
|
|
|
39,250 |
|
US government and agency securities |
|
|
— |
|
|
|
19,491 |
|
|
|
— |
|
|
|
19,491 |
|
Total financial assets |
|
$ |
5,290 |
|
|
$ |
58,741 |
|
|
$ |
— |
|
|
$ |
64,031 |
|
13
|
|
December 31, 2015 |
|
|||||||||||||
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
||||
Financial Assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Money market funds |
|
$ |
3,988 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
3,988 |
|
Reverse repurchase agreements |
|
|
— |
|
|
|
16,250 |
|
|
|
— |
|
|
|
16,250 |
|
US government and agency securities |
|
|
— |
|
|
|
3,768 |
|
|
|
— |
|
|
|
3,768 |
|
Total financial assets |
|
$ |
3,988 |
|
|
$ |
20,018 |
|
|
$ |
— |
|
|
$ |
24,006 |
|
The Company measures the fair value of money market funds on quoted prices in active markets for identical asset or liabilities. The Level 2 assets include reverse repurchase agreements and U.S. government and agency securities and are valued based on quoted prices for similar assets in active markets and inputs other than quoted prices that are derived from observable market data.
The Company evaluates transfers between levels at the end of each reporting period. There were no transfers between Level 1 and Level 2 during the periods presented.
10. Net Loss Per Share Attributable to Common Stockholders
The Company computed net loss attributable per common stockholder using the two-class method required for participating securities through the date of the IPO. Immediately prior to the IPO, all outstanding convertible preferred stock was converted into common stock (see Note 5). The Company considered convertible preferred stock to be participating securities. In the event that the Company had paid out distributions, holders of convertible preferred stock would have participated in the distribution.
The two-class method is an earnings (loss) allocation method under which earnings (loss) per share is calculated for common stock and participating security considering a participating security’s rights to undistributed earnings (loss) as if all such earnings (loss) had been distributed during the period. The convertible preferred stock did not have an obligation to fund losses and are therefore excluded from the calculation of basic net loss per share. Starting in the first quarter of 2015 in connection with the LLC Conversion, the Company’s Series A and B convertible preferred stock were entitled to receive noncumulative dividends and in preference to any dividends on shares of the Company’s common stock.
Basic and diluted net loss per share attributable to common stockholders is computed by dividing net loss attributable to common stock by the weighted-average number of common stock outstanding during the period. For net loss per share attributable to common stockholders for the three and nine months ended September 30, 2015, the effect of the LLC Conversion is presented prospectively from January 1, 2015 as none of the losses for the three and nine months ended September 30, 2015 were allocated to the members of Aeglea LLC. For periods in which the Company generated a net loss, the Company does not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti-dilutive. Additionally, the convertible preferred stock dividend is included in the loss attributable to common stockholders.
The following weighted-average equity instruments were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented:
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||
|
|
2016 |
|
|
2015 |
|
|
2016 |
|
|
2015 |
|
||||
Series A convertible preferred stock |
|
|
— |
|
|
|
2,172,520 |
|
|
|
816,677 |
|
|
|
2,172,520 |
|
Series B convertible preferred stock |
|
|
— |
|
|
|
4,999,976 |
|
|
|
1,879,553 |
|
|
|
3,726,832 |
|
Unvested restricted common stock |
|
|
95,415 |
|
|
|
139,837 |
|
|
|
105,996 |
|
|
|
161,979 |
|
Options to purchase common stock |
|
|
1,361,135 |
|
|
|
644,505 |
|
|
|
1,017,620 |
|
|
|
435,022 |
|
11. Research and License Agreements
University Research Agreement
In December 2013, the Company entered into a research agreement with the University of Texas at Austin (the “University”). Under the terms of this research agreement, the Company engaged the University to perform certain
14
nonclinical research activities related to the systemic depletion of amino acids for cancer therapy and rare disease therapy.
Under the research agreement, the Company was required to pay the University an annual amount not to exceed $386,000 during the one year term of the agreement from the effective date. The term and maximum expenditure limitation were subsequently extended and increased through five subsequent amendments through August 31, 2017 for a combined $1.8 million under the agreement, including an amendment in August 2016 increasing the maximum expenditure limitation by $750,000 for additional research to be performed by the University. The Company made payments to the University under the research agreement of $188,000 and $375,000 in the three months ended September 30, 2016 and 2015, respectively, and made payments of $645,000 and $563,000 in the nine months ended September 30, 2016 and 2015, respectively.
License Agreements
In December 2013, the Company entered into two license agreements with the University. Under the terms of each license agreement, the University granted the Company an exclusive worldwide license to develop, manufacture, and commercialize therapeutics related to the University’s engineered cysteine/cystine degrading enzymes and engineered methionine degrading enzymes for use in the treatment of human diseases.
Under each license agreement, the Company paid the University an up-front fee of $10,000 in 2013 and will pay annual license fees increasing from $5,000 in 2016 to $25,000 in 2018 and thereafter. The Company may be required to make future payments of up to $6.4 million contingent upon attainment of various development and regulatory approval milestones for the licensed product in any country. The milestone payments are payable in various amounts upon the start of different phases of clinical trials, application for, and receipt of regulatory approval, with $5.0 million payable upon the receipt of regulatory approval and a $500,000 payment payable on final regulatory approval of a second indication. Additionally, upon commercial sales of the product, the Company will be required to pay to the University a single-digit royalty on net sales of the licensed products in any country or region, if such product sales are ever achieved.
12. Related Party Transactions
The spouse of the Company’s Chief Executive Officer provides consulting services to the Company. Payments made to the spouse in consulting fees were $65,000 and $110,000 in the three months ended September 30, 2016 and 2015, respectively, and $389,000 and $332,000 in the nine months ended September 30, 2016 and 2015, respectively. The costs were recorded in Research and Development expenses. As of September 30, 2016 and December 31, 2015, the Company had an outstanding liability to the related party of $11,000, and $129,000, respectively.
One of the founders, a non-employee member of the Company’s Board of Directors, entered into a consulting agreement with the Company in 2014 under which the founder would receive $50,000 per year for a fixed number of hours of consulting and advisory services and receive 57,142 Common B shares (converted into 43,290 restricted stock awards and 13,852 stock options upon the LLC Conversion) with the vesting contingent on time and performance milestones being achieved. The Company paid $25,000 and $14,000 in the three months ended September 30, 2016 and 2015, respectively, and $50,000 and $39,000 in the nine months ended September 30, 2016 and 2015, respectively, to the Founder under the consulting agreement. As of September 30, 2016 and December 31, 2015, the Company had an outstanding liability to the related party of $9,000 and $0, respectively.
13. Commitments and Contingencies
The Company leases office space in Austin, TX under an operating lease that commenced in January 2015. The lease was amended in September 2016 to increase office space and extend the term to December 31, 2020. As provided in the lease amendment, monthly lease payments are subject to annual increases through the lease term. The Company recognizes rent expense on a straight-line basis over the noncancelable term of the lease.
The following table summarizes the Company’s future minimum lease commitments as of September 30, 2016 (in thousands):
15
Year ending December 31: |
|
|
|
|
2016 |
|
$ |
50 |
|
2017 |
|
|
263 |
|
2018 |
|
|
284 |
|
2019 |
|
|
292 |
|
2020 |
|
|
301 |
|
Total minimum lease payments |
|
$ |
1,190 |
|
Under the terms of the office lease agreement, the Company provided the lessor with a security deposit of $54,000. The lessor is entitled to retain all or any part of the security deposit for payment in the event of any uncured default by the Company under the terms of the lease. The security deposit requirement was reduced by $18,000 in January 2016 and returned to the Company. Pursuant to the terms of the lease amendment, the security deposit requirement was set at $39,000 until the expiration of the lease.
Rent expense for each of the three months ended September 30, 2016 and 2015 was $35,000. Rent expense for each of the nine months ended September 30, 2016 and 2015 was $105,000.
16
You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and related notes included in Part I, Item 1 of this Quarterly Report as well as the audited consolidated financial statements and notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations, included in our Prospectus dated April 6, 2016 filed with the Securities and Exchange Commission, or the SEC, pursuant to Rule 424(b)(4), which we refer to as the “Prospectus”. This discussion and other parts of this Quarterly Report contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section of this report entitled “Risk Factors.”
Overview
We are a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism that we believe will transform the lives of patients with inborn errors of metabolism and cancer. Our engineered human enzymes are designed to reduce the level of specific amino acids in the blood. In inborn errors of metabolism, or IEM, we are seeking to reduce the toxic levels of amino acids in patients. In oncology, we are seeking to reduce amino acid blood levels below the normal range where we believe we will be able to exploit the dependence of certain cancers on specific amino acids.
Our lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers which have shown to have a metabolic dependence on arginine. AEB1102 has demonstrated the ability to reduce blood arginine levels in nonclinical and oncology clinical studies supporting its use as a potential treatment of both Arginase I deficiency and those cancers predicted to be dependent on arginine for survival.
We have initiated three Phase 1 clinical trials for AEB1102. In October 2015, we initiated enrollment for a dose escalation trial in patients with advanced solid tumors and intend to initiate expansion arms in different tumor types in 2017. In June 2016, we initiated a clinical trial for the treatment of Arginase I deficiency, a urea cycle disorder that results in elevated circulating levels of the amino acid arginine, with the intent to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of AEB1102 in patients with this IEM. In July 2016, we initiated a clinical trial in patients with relapsed refractory acute myeloid leukemia, or AML, and myelodysplastic syndrome, or MDS, in the United States and Canada. We expect to complete enrollment in the dose escalation in 2017.
Since inception, we have devoted substantially all of our efforts and resources to identifying and developing product candidates, conducting nonclinical studies, initiating and conducting clinical trials, recruiting personnel and raising capital. To date, we have financed our operations primarily through private placements of our preferred stock, the initial public offering, or IPO, of our common stock, completed on April 12, 2016, and collection of a research grant. In connection with the IPO, we sold 5,481,940 shares of common stock for aggregate proceeds of $47.3 million net of underwriting discounts and commissions and offering costs.
We have no recorded revenue from product sales and all of our revenue to date has been grant revenue. Since our inception, and through September 30, 2016, we have raised an aggregate of $109.5 million to fund our operations through sale and issuance of convertible preferred and common equity securities and collected $8.1 million in grant proceeds. As of September 30, 2016, we had cash, cash equivalents, and marketable securities of $68.0 million.
We have incurred net losses in each year since inception. Our net losses were $16.2 million and $7.3 million for the nine months ended September 30, 2016 and 2015, respectively, and have resulted from costs incurred in connection with our research and development programs and from general and administrative expenses associated with our operations. As of September 30, 2016, we had an accumulated deficit of $39.8 million. We expect to continue to incur significant expenses and operating losses over the next several years. Our net losses may fluctuate significantly from quarter to quarter and from year to year. We anticipate that our expenses will increase significantly as we continue our clinical and diagnostic development activities for our lead product candidate, AEB1102; concurrently develop our pipeline product candidates; expand and protect our intellectual property portfolio; and hire additional personnel. In addition, we expect to incur additional costs associated with operating as a public company.
17
In September 2016, we announced the dosing of the first two patients in a Phase 1 trial of AEB1102 for the treatment of patients with Arginase I deficiency. The Phase 1 trial will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AEB1102 in patents with this IEM. Enrollment is expected to be completed in 2016 with topline data expected in the first half of 2017.
In September 2016, we announced the formation of and appointment of five leading experts to our Scientific Advisory Board to serve as a strategic resource to us by providing scientific and clinical insights to support our pipeline of engineered human enzymes.
In August 2016, we announced the dosing of the first patient in a Phase 1 trial of AEB1102 for the treatment of the hematological malignancies AML and MDS. The Phase 1 trial, conducted in the United States and Canada, is designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AEB1102. Enrollment is expected to be completed in 2017.
Components of Operating Results
Revenue
To date, we have recognized revenue solely from a research grant from the Cancer Prevention and Research Institute of Texas, or CPRIT, and have not generated any revenue from the sale of any of our product candidates. Our ability to generate product revenues, which we do not expect will occur for several years, if ever, will depend heavily on the successful development, regulatory approval and eventual commercialization of our product candidates.
In June 2015, we entered into a grant agreement with CPRIT, or the Grant Contract, for $19.8 million covering a three year period from June 1, 2014 through May 31, 2017. The grant allows us to receive funds in advance of costs and allowable expenses being incurred. We record the revenue as qualifying costs are incurred and there is reasonable assurance that the conditions of the award have been met for collection. Proceeds received prior to the costs being incurred or the conditions of the award being met are recognized as deferred revenue until the services are performed and the conditions of the award are met.
On a quarterly basis, we are required to submit a financial reporting package outlining the nature and extent of reimbursable costs paid and requesting reimbursement under the grant. At the end of each period, qualifying costs paid prior to reimbursement result in the recognition of a grant receivable.
Research and development expenses
Research and development expenses consist primarily of costs incurred for the discovery and development of our product candidates, most notably, our lead product candidate AEB1102. Since we currently do not have internal laboratory or manufacturing capabilities, we contract with external providers for nonclinical studies, clinical trials and manufacturing services. Our research and development expenses include:
|
∎ |
costs from acquiring clinical trial materials and services performed for contracted services with our strategic manufacturing partner; |
|
∎ |
fees paid to clinical trial sites, clinical research organizations, contract research organizations, contract manufacturing organizations, nonclinical research companies, and academic institutions; |
|
∎ |
employee and consultant-related expenses incurred, which include salaries, benefits, travel and share-based compensation; and |
|
∎ |
expenses incurred under license agreements with third parties. |
Research and development costs are expensed as incurred. Advance payments for goods or services to be rendered in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.
Research and development expenses have historically represented the largest component of our total operating expenses. We plan to increase our research and development expenses for the foreseeable future as we continue the development of our product candidates.
18
Our expenditures on current and future nonclinical and clinical development programs are subject to numerous uncertainties in timing and cost to completion. The duration, costs, and timing of clinical trials and development of our product candidates will depend on a variety of factors, including:
|
∎ |
the scope, rate of progress, and expenses of our ongoing research activities as well as any additional clinical trials and other research and development activities; |
|
∎ |
future clinical trial results; |
|
∎ |
uncertainties in clinical trial enrollment rates or drop-out or discontinuation rates of patients; |
|
∎ |
potential safety monitoring or other studies requested by regulatory agencies; |
|
∎ |
significant and changing government regulation; and |
|
∎ |
the timing and receipt of regulatory approvals, if any. |
The process of conducting the necessary clinical research to obtain FDA and other regulatory approval is costly and time consuming and the successful development of our product candidates is highly uncertain. The risks and uncertainties associated with our research and development projects are discussed more fully in Part II, Item 1A of this Quarterly Report titled “Risk Factors.” As a result of these risks and uncertainties, we are unable to determine with any degree of certainty the duration and completion costs of our research and development projects, or if, when, or to what extent we will generate revenues from the commercialization and sale of any of our product candidates that obtain regulatory approval. We may never succeed in achieving regulatory approval for any of our product candidates.
General and administrative expenses
General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in executive, finance, accounting, and human resources functions. Other significant costs include legal fees relating to corporate matters and fees for accounting and consulting services.
We expect that our general and administrative expenses will increase in the future to support our continued research and development activities, potential commercialization of our product candidates and the increased costs of operating as a public company. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside consultants, lawyers and accountants, among other expenses. Additionally, we will continue to incur increased costs associated with being a public company, including expenses related to services associated with maintaining compliance with NASDAQ listing rules and SEC requirements, insurance and investor relations costs.
Interest income
Interest income consists of interest earned on our cash, cash equivalents, and marketable securities.
Income taxes
Since inception in December 2013, through March 10, 2015, we were a Delaware LLC and elected to file as a partnership for federal and state income tax purposes through the year ended December 31, 2014. On March 10, 2015, we converted from a Delaware LLC to a Delaware corporation, and have subsequently filed a corporate income tax return for the year ended December 31, 2015. For tax purposes, we elected to be treated as a corporation under Subchapter C of Chapter 1 of the United States Internal Revenue Code, effective January 1, 2015. We therefore, were subject to federal and state tax expense beginning January 1, 2015.
We serve as a holding company for our seven wholly-owned subsidiary corporations and file consolidated corporate federal income tax returns. We use the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements and the tax bases of assets and liabilities. A valuation allowance is established against the deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. The deferred tax assets and liabilities are classified as noncurrent along with the related valuation allowance. Due to our lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance.
19
We recognize benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on the technical merits, as the largest amount of benefits that is more likely than not to be realized upon the ultimate settlement. Our policy is to recognize interest and penalties related to the unrecognized tax benefits as a component of income tax expense. To date, there have been no interest or penalties recognized in relation to the unrecognized tax benefits.
Critical Accounting Policies and Estimates
Our condensed consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and related disclosures. These estimates form the basis for judgments we make about the carrying values of our assets and liabilities, which are not readily apparent from other sources. We base our estimates and judgments on historical experience and on various other assumptions that we believe are reasonable under the circumstances. On an ongoing basis, we evaluate our estimates and assumptions. Our actual results may differ from these estimates under different assumptions or conditions.
Our critical accounting policies are those policies which require the most significant judgments and estimates in the preparation of our consolidated financial statements. We believe that the assumptions and estimates associated with our most critical accounting policies are those relating to accrued research and development costs and stock-based compensation.
There have been no significant changes in our critical accounting policies and estimates as compared to the critical accounting policies and estimates disclosed in Management’s Discussion and Analysis of Financial Condition and Operations included in our Prospectus, except for the determination of the fair value of our common stock, which was used in estimating the fair value of stock-based awards at grant date. Prior to our IPO, our stock was not publicly traded, therefore we estimated the fair value of our common stock as discussed in the Prospectus. Following our IPO, we established a policy of using the closing sale price per share of our common stock as quoted on the NASDAQ Global Market on the date of grant for purposes of determining the exercise price per share of our share-based awards to purchase common stock.
Results of Operations
Comparison of the Three Months Ended September 30, 2016 and 2015
The following table summarizes our results of operations for the three months ended September 30, 2016 and 2015, together with the changes in those items in dollars and as a percentage:
|
|
Three Months Ended September 30, |
|
|
Dollar |
|
|
|
|
|
||||||
|
|
2016 |
|
|
2015 |
|
|
Change |
|
|
% Change |
|
||||
|
|
(dollars in thousands) |
|
|
|
|
|
|||||||||
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Grant |
|
$ |
1,149 |
|
|
$ |
1,073 |
|
|
$ |
76 |
|
|
|
7 |
% |
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|